Aditxt Announces First AditxtEngage Event, Continuing Series of Investor Opportunities to Engage with Company

First AditxtEngage™ Event with Amro Albanna, CEO, to be held on Tuesday, October 6th at 4:30pm ET

Mountain View, CA – (NewMediaWire) – October 02, 2020 – Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, today announced the launch of AditxtEngage™, a continuing series of investor opportunities to engage with Aditxt.  

The first AditxtEngage™ event will be a live Q&A session held on Tuesday, October 6, 2020 from 4:30pm – 5:00pm ET. The kickoff speaker will be Amro Albanna, the Co-Founder and Chief Executive Officer of Aditxt. The event will be moderated by Chris Lahiji, Founder and President of LD Micro.  The event can be accessed by following this link: https://zoom.us/webinar/register/WN_3E04akpNTzuqnpv9kYvaBA

AditxtEngage™ is envisioned as a platform for engaging stakeholders with Aditxt and its mission.  It is intended to provide additional color and context about the Company’s growth and development. 

About Aditx Therapeutics

Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming. The immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system. The immune reprogramming technology is currently at the pre-clinical stage and is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. For more information, please visit: www.aditxt.com

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Forward looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company’s ongoing and planned product development; the Company’s intellectual property position; the Company’s ability to develop commercial functions; expectations regarding product launch and revenue; the Company’s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section entitled “Risk Factors” in the Company’s prospectus, dated September 1, 2020, that was filed with the Securities and Exchange Commission under File No. 333-248491, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s subsequent filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations:

PCG Advisory
Jeff Ramson

Chief Executive Officer

IR@aditxt.com
646-762-4518

www.aditxt.com